Highlights

  • Amplia Therapeutics (ASX:ATX) has entered a clinical trial collaboration with Eli Lilly to evaluate narmafotinib in combination with olomorasib.
  • The company is advancing multiple clinical programmes focused on pancreatic, lung and ovarian cancers.
  • A pancreatic cancer registration pathway has been developed with regulatory input.
  • Trial milestones through late 2026 and early 2027 are key areas for investors to monitor.

Amplia Therapeutics (ASX:ATX) is progressing a clinical-stage oncology pipeline centred on narmafotinib, a focal adhesion kinase (FAK) inhibitor being evaluated across several cancer indications.

The company reached an important development milestone in August 2026 through a clinical collaboration with Eli Lilly, adding another pathway for evaluating narmafotinib alongside a targeted cancer therapy.

With multiple studies scheduled to progress through late 2026 and early 2027, the key focus is whether clinical execution can translate early signals into larger-stage development opportunities.

Latest Development

In an announcement released in early August 2026, Amplia Therapeutics (ASX:ATX) entered a Clinical Trial Collaboration and Supply Agreement with Eli Lilly.

Under the agreement, Amplia's narmafotinib will be evaluated alongside Lilly's KRAS G12C inhibitor olomorasib in a Phase 1b/2b clinical trial for second-line advanced non-small cell lung cancer.

The study will be conducted across clinical sites in Australia and the United States.

Amplia will manage the trial and provide narmafotinib, while Lilly will provide olomorasib.

Financial terms of the collaboration were not disclosed.

Company Overview

Amplia Therapeutics (ASX:ATX) develops therapies targeting focal adhesion kinase, a protein associated with several cancer types.

Its lead candidate, narmafotinib (also known as AMP945), is designed as a selective FAK inhibitor.

The company is focused on cancers where fibrosis and tumour microenvironments may influence treatment response, particularly pancreatic and ovarian cancers.

Its clinical portfolio includes:

  • ACCENT: Evaluating narmafotinib with gemcitabine and nab-paclitaxel in first-line advanced pancreatic cancer.
  • AMPLICITY: Investigating narmafotinib with mFOLFIRINOX at Australian sites.
  • PRROSE: An ovarian cancer study being conducted with ANZGOG.

Recent Developments

Amplia Therapeutics (ASX:ATX) outlined a three-stage registration pathway for pancreatic cancer in its August 2026 Annual General Meeting presentation.

The pathway has been developed with regulatory input and includes ACCENT-mini, which has commenced with first patient dosing targeted for October 2026.

The company is also finalising the design of ACCENT-reg, a planned Phase 2b/3 study intended to support a potential regulatory submission.

Earlier ACCENT data presented by the company showed a complete response rate of 7.8% and disease control rate of 70%.

The company also reported median overall survival of 11.1 months, compared with historical chemotherapy-alone outcomes of approximately 8.5 months.

The company stated that no additional safety burden was observed in the reported data.

Financial and Operational Position

Amplia Therapeutics (ASX:ATX) remains a pre-revenue clinical-stage biotechnology company and does not pay dividends.

The company has not disclosed a current cash balance in the reviewed announcements.

Funding requirements will depend on the pace of clinical development, the number of active trials and future strategic arrangements.

The collaboration with Eli Lilly provides clinical development support but does not include disclosed commercial economics.

What Investors May Watch Next

Several clinical milestones are expected over the coming months.

Key areas to monitor include:

  • First patient dosing in ACCENT-mini, targeted for October 2026.
  • Completion of safety and pharmacokinetic review expected during the first quarter of 2027.
  • Commencement of the Lilly-partnered lung cancer study.
  • Recruitment progress for the PRROSE ovarian cancer study.
  • Further detail on the ACCENT-reg Phase 2b/3 study design.

The pace and quality of clinical execution will likely determine the next phase of investor interest.

Risks

Clinical development remains the primary risk for Amplia Therapeutics (ASX:ATX).

Early efficacy signals from smaller single-arm studies may not be replicated in larger randomised trials.

Historical chemotherapy comparisons are not equivalent to controlled clinical comparisons, and cancer Drug Development involves significant uncertainty.

Trial timelines can also change due to recruitment, regulatory or operational factors.

The Eli Lilly agreement is a clinical collaboration and supply arrangement rather than a licensing transaction, with no disclosed financial terms.

Amplia will require ongoing funding to support its clinical programmes, which may result in future Shareholder dilution.

Key Takeaways

Amplia Therapeutics (ASX:ATX) has entered a more advanced stage of development, supported by multiple clinical programmes and a collaboration with Eli Lilly.

The company's immediate focus is execution: progressing ACCENT-mini, advancing the Lilly-partnered study and developing a potential pancreatic cancer registration pathway.

While clinical outcomes remain uncertain, the number of upcoming milestones provides a defined schedule for investors tracking the company's progress through late 2026 and early 2027.